News | February 01, 2024
Zydus Lifesciences launches Rexigo
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Darolutamide is developed jointly by Bayer and Orion Corporation
Subscribe To Our Newsletter & Stay Updated
